-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Amarin Co. Plc (NASDAQ:AMRN) Short Interest Update
Amarin Co. Plc (NASDAQ:AMRN) Short Interest Update
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 9,560,000 shares, a drop of 24.8% from the August 31st total of 12,720,000 shares. Based on an average trading volume of 3,570,000 shares, the short-interest ratio is currently 2.7 days.
Amarin Stock Performance
Shares of AMRN stock opened at $1.10 on Friday. The stock has a market capitalization of $443.53 million, a P/E ratio of -4.40 and a beta of 1.87. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.89. Amarin has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.
Get Amarin alerts:Amarin (NASDAQ:AMRN – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $94.44 million during the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. The company's revenue for the quarter was down 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. On average, research analysts forecast that Amarin will post -0.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded shares of Amarin from a "sell" rating to a "hold" rating in a research report on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Amarin currently has an average rating of "Hold" and an average target price of $2.50.Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Creative Planning grew its holdings in shares of Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin during the 1st quarter worth approximately $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin during the 1st quarter worth approximately $34,000. Kalos Management Inc. acquired a new position in Amarin during the 1st quarter worth approximately $37,000. Finally, Advisor Resource Council acquired a new position in Amarin during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
About Amarin
(Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 9,560,000 shares, a drop of 24.8% from the August 31st total of 12,720,000 shares. Based on an average trading volume of 3,570,000 shares, the short-interest ratio is currently 2.7 days.
爱马林股份有限公司(纳斯达克:AMRN-GET评级)是空头股数9月份大幅下跌的目标。截至9月15日,空头股数共有9,560,000股,较8月31日的12,720,000股减少24.8%。以平均成交量3,57万股计算,目前短息比为2.7天。
Amarin Stock Performance
Amarin股票表现
Shares of AMRN stock opened at $1.10 on Friday. The stock has a market capitalization of $443.53 million, a P/E ratio of -4.40 and a beta of 1.87. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.89. Amarin has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.
AMRN股票上周五开盘报1.10美元。该股市值为4.4353亿美元,市盈率为-4.40,贝塔系数为1.87。该公司的50日移动均线价格为1.32美元,200日移动均线价格为1.89美元。Amarin的52周低点为1.04美元,52周高位为5.24美元。
Amarin (NASDAQ:AMRN – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $94.44 million during the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. The company's revenue for the quarter was down 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. On average, research analysts forecast that Amarin will post -0.36 EPS for the current fiscal year.
爱马林(纳斯达克代码:AMRN-GET Rating)上一次公布季度收益数据是在8月3日星期三。这家生物制药公司公布了该季度每股收益(0.18美元),低于分析师普遍预期的(0.07美元)至(0.11美元)。该业务本季度营收为9444万美元,而分析师预期为8821万美元。Amarin的净利润率为负21.05%,股本回报率为负13.63%。该公司本季度营收同比下降38.9%。去年同期,该公司公布的每股收益为0.02美元。研究分析师平均预测,阿马林本财年每股收益将达到0.36欧元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors have recently made changes to their positions in the business. Creative Planning grew its holdings in shares of Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin during the 1st quarter worth approximately $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin during the 1st quarter worth approximately $34,000. Kalos Management Inc. acquired a new position in Amarin during the 1st quarter worth approximately $37,000. Finally, Advisor Resource Council acquired a new position in Amarin during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
机构投资者最近对他们在该业务中的头寸进行了调整。创意策划在第二季度增持了66.4%的Amarin股票。Creative Planning现在拥有这家生物制药公司17,285股股票,价值26,000美元,上个季度又购买了6,900股。Quantbot Technologies LP在第一季度收购了阿马林的一个新头寸,价值约3.1万美元。温斯罗普咨询集团在第一季度收购了阿马林的一个新头寸,价值约3.4万美元。Kalos Management Inc.在第一季度收购了阿马林的一个新头寸,价值约3.7万美元。最后,顾问资源委员会在第二季度在阿马林获得了一个价值约3.7万美元的新职位。机构投资者和对冲基金持有该公司34.15%的股票。
About Amarin
关于阿玛林
(Get Rating)
(获取评级)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制药公司,在美国、德国、加拿大、黎巴嫩和阿拉伯联合酋长国从事心血管疾病治疗药物的开发和商业化。它的主要产品是Vascepa,一种仅限处方的omega-3脂肪酸产品,用作饮食的辅助产品,用于降低患有严重高甘油三酯血症的成年患者的甘油三酯水平。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- 免费获取StockNews.com关于Amarin的研究报告(Amrn)
- Humana证明垂直整合的医疗保健工作
- 关于这个熊市,Cintas能教给投资者什么?
- 这家小盘股医疗保健公司的表现好于其指数
- 值得一看的2只赌场股票
- 黑莓股价下跌,业绩再次不温不火
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿马林日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Amarin和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧